CVS Health Corporation $CVS Position Boosted by Assetmark Inc.

Key Points

• Assetmark Inc. increased its CVS stake by 8%, buying 54,111 shares to hold 732,669 shares worth about $58.15 million, and institutional investors now own roughly 80.66% of the company.
• Analysts are broadly positive—20 Buy ratings vs. 3 Hold—with an average price target of $94.95 and recent upgrades/price-target increases from firms including JPMorgan and Sanford C. Bernstein.
• CVS beat expectations with Q4 EPS of $1.09 (vs. $1.00 est.) and revenue of $105.69B (vs. $103.67B), set FY2026 EPS guidance of $5.94–6.14, and announced a $0.665 quarterly dividend (≈3.4% yield) despite a high payout ratio (~193%).

Assetmark Inc. increased its position in CVS Health Corporation (NYSE:CVS - Free Report) by 8.0% in the fourth quarter, according to its most recent disclosure with the SEC. The institutional investor owned 732,669 shares of the pharmacy operator's stock after purchasing an additional 54,111 shares during the period. Assetmark Inc. owned 0.06% of CVS Health worth $58,145,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently bought and sold shares of the company. Harbor Capital Advisors Inc. lifted its stake in CVS Health by 72.1% during the third quarter. Harbor Capital Advisors Inc. now owns 339 shares of the pharmacy operator's stock worth $26,000 after purchasing an additional 142 shares during the last quarter. Caitong International Asset Management Co. Ltd increased its stake in CVS Health by 407.2% during the third quarter. Caitong International Asset Management Co. Ltd now owns 350 shares of the pharmacy operator's stock valued at $26,000 after purchasing an additional 281 shares during the last quarter. Corundum Trust Company INC acquired a new stake in shares of CVS Health during the third quarter worth $29,000. GoalVest Advisory LLC bought a new position in shares of CVS Health in the 4th quarter worth about $32,000. Finally, SOA Wealth Advisors LLC. boosted its holdings in shares of CVS Health by 36.9% in the 3rd quarter. SOA Wealth Advisors LLC. now owns 486 shares of the pharmacy operator's stock valued at $37,000 after buying an additional 131 shares during the period. Institutional investors and hedge funds own 80.66% of the company's stock.

Analyst Ratings Changes

A number of equities research analysts recently weighed in on CVS shares. JPMorgan Chase & Co. boosted their price objective on shares of CVS Health from $93.00 to $101.00 and gave the company an "overweight" rating in a research report on Wednesday, December 17th. Leerink Partners restated an "outperform" rating and issued a $98.00 target price on shares of CVS Health in a research note on Thursday, March 5th. Sanford C. Bernstein raised CVS Health from a "market perform" rating to an "outperform" rating and upped their target price for the company from $91.00 to $94.00 in a report on Thursday, March 12th. Argus dropped their price target on CVS Health from $91.00 to $90.00 and set a "buy" rating on the stock in a research report on Wednesday, January 28th. Finally, TD Cowen restated a "buy" rating on shares of CVS Health in a research report on Friday, March 13th. Twenty equities research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average price target of $94.95.

CVS Health Stock Performance

Shares of CVS stock opened at $77.63 on Wednesday. CVS Health Corporation has a 12-month low of $58.35 and a 12-month high of $85.15. The company has a debt-to-equity ratio of 0.80, a current ratio of 0.84 and a quick ratio of 0.63. The firm has a market capitalization of $99.49 billion, a price-to-earnings ratio of 56.25, a price-to-earnings-growth ratio of 0.82 and a beta of 0.51. The business has a 50 day simple moving average of $75.99 and a 200 day simple moving average of $77.84.

CVS Health (NYSE:CVS - Get Free Report) last announced its quarterly earnings results on Tuesday, February 10th. The pharmacy operator reported $1.09 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.00 by $0.09. The company had revenue of $105.69 billion during the quarter, compared to analyst estimates of $103.67 billion. CVS Health had a return on equity of 11.31% and a net margin of 0.44%.The firm's quarterly revenue was up 8.2% on a year-over-year basis. During the same quarter in the previous year, the firm posted $1.19 EPS. CVS Health has set its FY 2026 guidance at 5.940-6.140 EPS. On average, equities research analysts anticipate that CVS Health Corporation will post 5.89 EPS for the current year.

CVS Health Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Monday, May 4th. Shareholders of record on Thursday, April 23rd will be paid a dividend of $0.665 per share. The ex-dividend date of this dividend is Thursday, April 23rd. This represents a $2.66 annualized dividend and a yield of 3.4%. CVS Health's dividend payout ratio (DPR) is presently 192.75%.

CVS Health Company Profile

CVS Health Corporation is a diversified healthcare company that operates a large network of retail pharmacies, pharmacy benefit management services and health care solutions. Headquartered in Woonsocket, Rhode Island, the company traces its roots to the early 1960s and has grown into an integrated provider of prescription drugs, over‑the‑counter products, clinical services and health insurance offerings. Its operating model combines retail pharmacy locations and in‑store clinics with broader pharmacy and health plan capabilities.

Key business activities include CVS Pharmacy retail operations, MinuteClinic walk‑in medical clinics and HealthHUB locations that offer expanded clinical services.

Want to see what other hedge funds are holding CVS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for CVS Health Corporation (NYSE:CVS - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.